SCIENTIFIC ABSTRACT 
Replication incompetent, recombination incompetent retroviral 
vectors (GINa and LNL6) will be used to mark autologous peripheral 
blood and marrow cells removed and stored from patients with CLL 
following treatment with conventional dose chemotherapy. This 
study is designed to determine the efficacy of purging and the 
origin of relapse following autologous bone marrow transplant 
(infused autologous cells or cells left in the systemic circulation 
following preparative therapy for the bone marrow transplantation) . 
We estimate that on the average 6 x 10 7 CD34 cells will be infused 
and that in these, there will be between 200 and 20,000 neoplastic 
cells marked with the retrovirus. This protocol will also determine 
if the peripheral blood or marrow is more heavily contaminated with 
neoplastic cells after the conventional dose therapy which is used 
before storage of the autologous marrow or peripheral blood cells. 
[410] 
Recombinant DNA Research, Volume 16 
